Research Area: Cardiovascular Disease Biological Activity: Candesartan (Atacand) is an angiotensin II receptor antagonist with an IC50 of 15 µg/kg.It reduced the risk of developing hypertension by nearly two-thirds during this period. In the last two years of the study, all participants were switched to placebo. By the end of the study, candesartan had significantly reduced the risk of hypertension, by more than 15%. [1][2] |